Evaluation of a Lateral Flow Immunoassay COVIDTECH^® SARS-CoV-2 IgM/IgG Antibody Rapid Test

Julien Exinger (1) , Cédric Hartard (2, 3) , Fanny Lafferrière (1) , Christelle Fenninger (1) , Loic Charbonnière (4) , Hélène Jeulin (2, 3)

1 Centre hospitalier de Haguenau
2 LCPME - Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement
3 Service de Virologie [CHRU Nancy]
4 DSA-IPHC - Département Sciences Analytiques et Interactions Ioniques et Biomoléculaires

The new epidemic coronavirus SARS-CoV-2 is responsible for severe respiratory illness (i.e. COVID-19). RT-PCR is the gold standard in COVID-19 diagnosis and is performed on respiratory samples, while serological tests may contribute to diagnosis and permit seroprevalence studies. The lateral flow immunoassay (LFIA) PolyDTech simultaneously detects anti-SARS-CoV-2 IgM and IgG using a Sprotein recombinant antigen and has been independently evaluated in two laboratories. The specificity evaluated on 53 pre-pandemic samples reached 100% for IgM and IgG. Analyzing samples from patients with RT-PCR-confirmed infection, IgM/IgG antibodies were detected in 18/26 (69%)

Mots clés: SARS-CoV-2; COVID-19; serological diagnosis; Flow lateral immunoassay

Domaines: Ingénierie biomédicale; Immunité adaptative; Maladies émergentes; Maladies infectieuses; Virologie

Julien Exinger, Cédric Hartard, Fanny Lafferrière, Christelle Fenninger, Loic Charbonnière, et al.. Evaluation of a Lateral Flow Immunoassay COVIDTECH^® SARS-CoV-2 IgM/IgG Antibody Rapid Test. Japanese Journal of Infectious Diseases, 2022, 75 (4), pp.334-340. ⟨10.7883/yoken.JJID.2021.273⟩. ⟨hal-03859205⟩